Mesoblast Company

A regenerative medicine company developing biologic products for inflammatory ailments, cardiovascular disease and back pain
Technology: diagnostics
Industry: Cell Therapy
Headquarters: Melbourne, Victoria, Australia
Founded Date: 2004
Employees Number: 51-100
Funding Status: IPO
Investors Number: 2
Total Funding: 227295275 USD
Estimated Revenue: $10M to $50M
Last Funding Date: 2020-05-13
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership